Display options
Cite
Vannitamby A, Saad MI, Aloe C, et al. Aspirin-Triggered Resolvin D1 Reduces Proliferation and the Neutrophil to Lymphocyte Ratio in a Mutant KRAS-Driven Lung Adenocarcinoma Model. Cancers (Basel). 2021;13(13)doi: 10.3390/cancers13133224.
Vannitamby, A., Saad, M. I., Aloe, C., Wang, H., Kumar, B., Vlahos, R., Selemidis, S., Irving, L., Steinfort, D., Jenkins, B. J., & Bozinovski, S. (2021). Aspirin-Triggered Resolvin D1 Reduces Proliferation and the Neutrophil to Lymphocyte Ratio in a Mutant KRAS-Driven Lung Adenocarcinoma Model. Cancers, 13(13), . https://doi.org/10.3390/cancers13133224
Vannitamby, Amanda, et al. "Aspirin-Triggered Resolvin D1 Reduces Proliferation and the Neutrophil to Lymphocyte Ratio in a Mutant KRAS-Driven Lung Adenocarcinoma Model." Cancers vol. 13,13 (2021). doi: https://doi.org/10.3390/cancers13133224
Vannitamby A, Saad MI, Aloe C, Wang H, Kumar B, Vlahos R, Selemidis S, Irving L, Steinfort D, Jenkins BJ, Bozinovski S. Aspirin-Triggered Resolvin D1 Reduces Proliferation and the Neutrophil to Lymphocyte Ratio in a Mutant KRAS-Driven Lung Adenocarcinoma Model. Cancers (Basel). 2021 Jun 28;13(13). doi: 10.3390/cancers13133224. PMID: 34203378; PMCID: PMC8268479.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2021 Jun 28;13(13). doi: 10.3390/cancers13133224.

Aspirin-Triggered Resolvin D1 Reduces Proliferation and the Neutrophil to Lymphocyte Ratio in a Mutant KRAS-Driven Lung Adenocarcinoma Model.

Cancers

Amanda Vannitamby, Mohamed I Saad, Christian Aloe, Hao Wang, Beena Kumar, Ross Vlahos, Stavros Selemidis, Louis Irving, Daniel Steinfort, Brendan J Jenkins, Steven Bozinovski

Affiliations

  1. School of Health & Biomedical Sciences, RMIT University, Bundoora 3083, Australia.
  2. Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton 3168, Australia.
  3. Department of Molecular Translational Science, School of Clinical Sciences, Monash University, Clayton 3168, Australia.
  4. Department of Anatomical Pathology, Monash Health, Clayton 3168, Australia.
  5. Department of Respiratory Medicine, Royal Melbourne Hospital, Parkville 3050, Australia.

PMID: 34203378 PMCID: PMC8268479 DOI: 10.3390/cancers13133224

Abstract

Tumour-associated neutrophils (TANs) can support tumour growth by suppressing cytotoxic lymphocytes. AT-RvD1 is an eicosanoid that can antagonise neutrophil trafficking instigated by ALX/FPR2 ligands such as serum amyloid A (SAA). We aimed to establish whether SAA and ALOX5 expression associates with TANs and investigate the immunomodulatory actions of AT-RvD1 in vivo. MPO-positive neutrophils were quantified in tumour blocks from lung adenocarcinoma (

Keywords: ALOX5; FPR2; SAA; adenocarcinoma; aspirin; inflammation; lung cancer; neutrophils; resolution; resolvin-D1

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the dec

References

  1. Lancet. 2011 Jan 1;377(9759):31-41 - PubMed
  2. Annu Rev Med. 2007;58:239-52 - PubMed
  3. Front Pharmacol. 2010 Dec 24;1:143 - PubMed
  4. Proc Natl Acad Sci U S A. 2012 Jan 17;109(3):935-40 - PubMed
  5. Cell Rep. 2015 Feb 3;10(4):562-73 - PubMed
  6. Crit Rev Oncol Hematol. 2013 Oct;88(1):218-30 - PubMed
  7. J Clin Oncol. 2017 Jul 1;35(19):2184-2192 - PubMed
  8. J Exp Clin Cancer Res. 2021 Apr 12;40(1):129 - PubMed
  9. Clin Sci (Lond). 2015 Sep;129(6):489-504 - PubMed
  10. J Biol Chem. 2002 Feb 8;277(6):4374-9 - PubMed
  11. Cancer Prev Res (Phila). 2018 Nov;11(11):727-734 - PubMed
  12. Nat Commun. 2015 Mar 03;6:6285 - PubMed
  13. Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):18232-7 - PubMed
  14. Nat Commun. 2017 Feb 01;8:14381 - PubMed
  15. J Clin Invest. 2014 Dec;124(12):5466-80 - PubMed
  16. Oncotarget. 2016 Jun 14;7(24):35843-35852 - PubMed
  17. Am J Respir Crit Care Med. 2013 Jul 15;188(2):179-86 - PubMed
  18. Oncogene. 2011 Sep 8;30(36):3887-99 - PubMed
  19. J Neuroinflammation. 2018 Jul 6;15(1):200 - PubMed
  20. J Mol Diagn. 2019 Mar;21(2):186-197 - PubMed
  21. Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):18033-4 - PubMed
  22. Ann Oncol. 2017 Mar 1;28(3):642-650 - PubMed
  23. Br J Pharmacol. 2016 Feb;173(4):635-48 - PubMed
  24. Eur J Immunol. 2014 Jun;44(6):1672-84 - PubMed
  25. J Immunol. 2016 Jan 15;196(2):891-901 - PubMed
  26. J Lipid Res. 2009 Apr;50 Suppl:S40-5 - PubMed
  27. Thorax. 2017 Dec;72(12):1140-1143 - PubMed
  28. J Immunother Cancer. 2019 Feb 6;7(1):32 - PubMed
  29. J Exp Med. 2002 Oct 21;196(8):1025-37 - PubMed
  30. Genes Dev. 2007 Jul 15;21(14):1714-9 - PubMed
  31. Biochem Biophys Res Commun. 2004 Feb 6;314(2):363-9 - PubMed
  32. Oncol Lett. 2017 Aug;14(2):2075-2080 - PubMed
  33. EMBO Mol Med. 2019 Apr;11(4): - PubMed
  34. Genes Dev. 2001 Dec 15;15(24):3243-8 - PubMed
  35. Pharmacol Ther. 2013 Dec;140(3):280-9 - PubMed
  36. Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6292-6297 - PubMed
  37. Proc Natl Acad Sci U S A. 1995 Oct 10;92(21):9475-9 - PubMed
  38. J Exp Med. 2018 Jan 2;215(1):115-140 - PubMed
  39. Clin Cancer Res. 2012 Nov 15;18(22):6169-77 - PubMed
  40. Nat Immunol. 2010 Nov;11(11):1039-46 - PubMed
  41. Cancer Res. 2016 Feb 15;76(4):866-76 - PubMed
  42. Cancer. 2012 Mar 15;118(6):1726-37 - PubMed
  43. J Thorac Oncol. 2015 Sep;10(9):1243-1260 - PubMed

Publication Types

Grant support